Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* TANG KEVIN C	2. Issuer Name and Ticker or Trading Symbol LA JOLLA PHARMACEUTICAL CO [ LJPC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) 4747 EXECUTIVE DRIVE, SUITE 210	3. Date of Earliest Transaction (MM/DD/YYYY) 8/12/2020
(Street) SAN DIEGO, CA 92121 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	8/12/2020		P		43513	A	$3.4661 ⁽¹⁾	8738987	I ⁽²⁾	By LP ⁽²⁾
Common Stock	8/13/2020		P		219465	A	$3.6479 ⁽³⁾	8958452	I ⁽²⁾	By LP ⁽²⁾
Common Stock	8/14/2020		P		168669	A	$3.8756 ⁽⁴⁾	9127121	I ⁽²⁾	By LP ⁽²⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.415 to $3.54. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 4 herein.
(2)	The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
(3)	The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.71.
(4)	The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.685 to $3.95.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
TANG KEVIN C 4747 EXECUTIVE DRIVE, SUITE 210 SAN DIEGO, CA 92121	X	X
TANG CAPITAL PARTNERS LP 4747 EXECUTIVE DRIVE, SUITE 210 SAN DIEGO, CA 92121		X
TANG CAPITAL MANAGEMENT LLC 4747 EXECUTIVE DRIVE, SUITE 210 SAN DIEGO, CA 92121		X
Hearne Michael S 4747 EXECUTIVE DRIVE, SUITE 210 SAN DIEGO, CA 92121			Chief Financial Officer

Signatures
/s/ Kevin Tang		8/14/2020
^**Signature of Reporting Person		Date
/s/ Kevin Tang, Managing Member of Tang Capital Management, LLC, General Partner		8/14/2020
^**Signature of Reporting Person		Date
/s/ Kevin Tang, Managing Member		8/14/2020
^**Signature of Reporting Person		Date
/s/ Michael Hearne		8/14/2020
^**Signature of Reporting Person		Date